Tirzepatide
Dual agonist research | Diabetes • Obesity • Outcomes
Common names: Mounjaro · Zepbound · dual GIP GLP-1 agonist · GIP/GLP-1 · SURMOUNT · SURPASS
- Evidence searched through
- August 24, 2026
- Last reviewed
- August 24, 2026
- Current version
- 1.0
4V Take
What the research shows.
Tirzepatide has a strong human evidence base for diabetes and weight management, and it is already approved for several uses. It also has important data in sleep apnea and obesity-related heart failure. The results are substantial, but that does not mean it is automatically better for every outcome. Nausea and other digestive side effects are common.
Explore the evidenceResearch Interest
Why are people interested?
Researchers are studying Tirzepatide across the approved public questions in this record. Those questions are areas of research interest, not guaranteed outcomes.
Evidence Context
What have researchers looked at?
This approved record brings together the research settings represented in its selected public sources. Evidence settings answer different questions, so human, animal, laboratory, and research-review findings stay distinct.
Current research context
Research stage describes the maturity of the current topic record. Source context describes the evidence settings represented in the selected public sources below; they are not interchangeable.
- Research stage
- Established for approved indications
- Selected source context
- Human
At a Glance
Research snapshot.
- 01Human Research
Extensive phase 3 program - 02Research Stage
Established for approved indications - 03Broader Outcomes
Developing - 04Regulatory Context
FDA context kept separate
Research Pathway
Follow the questions.
Choose a pathway to read its approved 4V Take. Each view stays focused on one question at a time.
4V Take
Tirzepatide is a dual GIP/GLP-1 receptor agonist with FDA-approved products for type 2 diabetes and chronic weight management.
- Evidence bucket
- mixed
- Research stage
- established
- Route / format
- FDA-approved products; regulatory context
Explore the evidence
human direct
SURMOUNT-1.
human direct
SURMOUNT-5.
human direct
SURPASS-CVOT.
4V Take
In SURMOUNT-1, tirzepatide produced large mean weight reductions over 72 weeks in adults with obesity/overweight without diabetes.
- Evidence bucket
- human clinical
- Research stage
- established
- Route / format
- adults with obesity/overweight without diabetes; 72 weeks
Explore the evidence
human direct
SURMOUNT-1.
human direct
SURMOUNT-5.
human direct
SURMOUNT-OSA.
Related pathways
4V Take
In SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide in adults with obesity without diabetes; mean change −20.2% vs −13.7% at week 72.
- Evidence bucket
- human clinical
- Research stage
- established
- Route / format
- adults with obesity without diabetes; week 72
Explore the evidence
human direct
SURMOUNT-1.
human direct
SURMOUNT-5.
human direct
SURMOUNT-OSA.
Related pathways
4V Take
In SURPASS-CVOT, tirzepatide was noninferior, but not statistically superior, to dulaglutide for major cardiovascular events.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- high-risk type 2 diabetes; dulaglutide comparator
Explore the evidence
human direct
SURMOUNT-1.
human direct
SURMOUNT-5.
human direct
SURPASS-CVOT.
4V Take
In adults with obesity and moderate-to-severe OSA, tirzepatide improved apnea-hypopnea index and other sleep-related outcomes; Zepbound later received FDA approval for this indication.
- Evidence bucket
- human clinical
- Research stage
- established
- Route / format
- adults with obesity and moderate-to-severe OSA
Explore the evidence
human direct
SURMOUNT-OSA.
human direct
SURMOUNT-1.
human direct
SURMOUNT-5.
Related pathways
4V Take
In obesity-related HFpEF, tirzepatide reduced the worsening-HF/CV-death composite in SUMMIT, with benefit driven mainly by fewer worsening HF events.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- obesity-related HFpEF
Explore the evidence
human direct
SUMMIT HFpEF + obesity.
human direct
SURMOUNT-1.
human direct
SURMOUNT-5.
4V Take
GI adverse events are common and often occur during escalation.
- Evidence bucket
- human clinical
- Research stage
- established
- Route / format
- tolerability context
Explore the evidence
human direct
SURMOUNT-1.
human direct
SURMOUNT-5.
human direct
SURPASS-CVOT.
Related pathways
Selected Sources
Explore the evidence.
Open an approved public source to inspect its study context, limitations, and original record where available.
human direct
SURMOUNT-1.
2022 · URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 · peer reviewed
human direct
SURMOUNT-5.
2025 · URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2416394 · peer reviewed
human direct
SURPASS-CVOT.
2025 · URL: https://www.nejm.org/doi/10.1056/NEJMoa2505928 · peer reviewed
human direct
SURMOUNT-OSA.
2024 · URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2404881 · peer reviewed
human direct
SUMMIT HFpEF + obesity.
2024 · URL: https://www.nejm.org/doi/10.1056/NEJMoa2410027 · peer reviewed
Research Status
Living research, deliberately tracked.
- Evidence searched globally through:
- August 24, 2026
- Last reviewed
- August 24, 2026
- Version
- 1.0
What Changed
Current record.
No later approved public release is available beyond the current topic record.
Evidence Boundaries
What are researchers still working out?
Study settings, measures, and limitations matter. A mechanism does not establish an outcome, animal or laboratory findings do not establish a human benefit, and a small study does not create consensus. Open each selected source for the approved record behind its finding.
Related Research
Continue with context.
Connections are limited to approved topic context. Each linked topic keeps its own evidence boundaries and Research Stage.
Retatrutide
Common comparisonBoth topics cover multi-receptor metabolic therapeutics while retaining their distinct research and regulatory contexts.
Research Stage: Phase 3
Compare the current Research Stage on each topic; they are not interchangeable.
Semaglutide
Common comparisonBoth topics cover prescription incretin-based therapies, while their receptor profiles, trial programs, and regulatory contexts remain distinct.
Research Stage: Established
Compare the Research Stage and regulatory context on each page; the therapies are not interchangeable.
GLP-1 Biology
Foundational biologyGLP-1 Biology provides pathway context for one receptor included in tirzepatide’s approved dual-agonist profile.
Research Stage: Foundational / Established
Pathway biology and therapeutic evidence remain separate.
GIP Biology
Foundational biologyGIP Biology provides pathway context for one receptor included in tirzepatide’s approved dual-agonist profile.
Research Stage: Foundational / Developing
Native physiology and therapeutic evidence remain separate.
Save / Follow
Keep this research close.
Save and Follow remain private account preferences. Following does not activate monitoring or notifications.
Loading member research actions.